NTLA

Intellia CFO Edward Dulac III sells $84,186 in stock

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Canaccord reiterates Intellia stock rating on positive trial data

Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

H.C. Wainwright reiterates Intellia stock rating on positive trial data

Citizens reiterates Intellia stock rating on positive trial data

Why Is NTLA Stock Jumping 5% Premarket Today?

Intellia Therapeutics Reports Additional Positive Phase 3

Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution

Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update

Intellia Therapeutics to Report Additional Phase 3 HAELO

Intellia to present Phase 3 gene editing trial data at congress

Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?